Peptides for Weight Loss: Which Are Approved Medicines, Which Are Research Chemicals

Type the word “peptides” into a search bar this winter and the autocomplete tells the story: peptides for weight loss, peptides near me, peptides vs Ozempic. The surge has a clear trigger. Through 2025, US regulators declared the shortages of semaglutide and tirzepatide over, which closed the temporary window that had allowed pharmacies to mass-produce copies. Many people who had been using those copies went looking for alternatives, and a crowded market of “research peptide” websites was waiting for them, as of January 2026.

The trouble is that the same six-letter word now covers a medicine studied in more than 17,000 people and a powder in a vial labeled “not for human consumption.” A peptide is simply a short chain of amino acids, the building blocks of protein. Insulin is one. So is the sweetener aspartame. Chemistry does not tell you whether something is safe or whether it works.

This piece sorts the shelf. Which peptides are approved medicines with graded evidence, which are still in trials, and which are chemicals with a marketing budget and nothing else.

What is a peptide, and why does one word cover both medicines and lab chemicals?

Start with the chemistry, because that is where the confusion begins. Proteins are long chains of amino acids, often hundreds of links long. A peptide is a short chain, usually fewer than about 50 amino acids. Your body makes thousands of them as messengers: hormones that tell the pancreas to release insulin, signals that tell the brain you have eaten enough, factors that nudge the pituitary gland to release growth hormone.

Because peptides are messengers, drug developers have long copied them. Insulin, used since the 1920s, is a peptide hormone. Oxytocin, given during labor, is a peptide. Semaglutide, the active ingredient in Ozempic and Wegovy, is a modified copy of a gut hormone called GLP-1. Each of these went through the same path: laboratory work, animal studies, then randomized controlled trials, the gold-standard studies in which people are assigned by chance to a treatment or a placebo so the two groups can be compared fairly.

The word “peptide” also appears on products that never took that path. Anyone with the right equipment can synthesize a short amino-acid chain, and a chain that showed an interesting effect in mice in 2004 can be sold online today under a “research use only” label. Nothing about being a peptide makes a compound gentle, natural or safe. Some of the most potent toxins in nature, including the venom of certain cone snails, are peptides.

So when a headline or a social feed says “peptides for weight loss,” the useful reflex is to ask a narrower question: which peptide, studied in how many humans, and approved by whom for what? The rest of this article applies that question, one compound at a time.

What changed recently to put peptides for weight loss in the headlines

The prescription side of this story moved fast over five years. In June 2021, US regulators approved semaglutide for chronic weight management in adults with obesity, or with overweight plus a weight-related condition, based on the STEP trials published in the New England Journal of Medicine. In November 2023, tirzepatide, which acts on two gut-hormone receptors instead of one, received the same approval after the SURMOUNT-1 trial. In March 2024, semaglutide’s label was expanded to include reducing the risk of major cardiovascular events in adults with established heart disease and overweight or obesity, following the SELECT trial of 17,604 participants.

Demand outran supply. During the shortage years, US law allowed licensed pharmacies to compound versions of these peptides, and telehealth companies built businesses around them. When regulators confirmed in 2025 that both shortages had resolved, the legal basis for routine compounding ended, with short wind-down periods. That is the moment the phrase “research peptides” began climbing in search.

Meanwhile, the pipeline kept publishing. Late-stage trials of retatrutide, which acts on three receptors, and of the combination cagrilintide-semaglutide reported results through 2025, and an oral form of semaglutide for weight management moved through regulatory review. None of these pipeline products are peptides you can lawfully buy for weight loss today, and the online sellers that advertise them are not offering the tested medicine.

In the UK, the NHS began a phased rollout of tirzepatide through primary care in 2025, prioritized by body mass index and coexisting conditions, which brought the same questions to a second large audience. The pattern is consistent across countries: real medicines with real evidence, a supply squeeze, and a grey market that borrowed the vocabulary.

Are peptides the same as Ozempic?

A clean answer: Ozempic is a peptide, but most things sold as “peptides” are not Ozempic, and many are nothing like it.

Ozempic and Wegovy both contain semaglutide. The two brands differ in the condition they are approved to treat, type 2 diabetes for Ozempic and chronic weight management for Wegovy, and in how the prescribing clinician uses them. Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1, or glucagon-like peptide-1, is a hormone your intestine releases after a meal; a receptor agonist is a molecule that fits into the same lock as the natural hormone and switches it on. Semaglutide is engineered to resist breakdown so it stays active for days rather than the two minutes natural GLP-1 lasts.

Tirzepatide, sold as Zepbound for weight management and Mounjaro for diabetes, activates both the GLP-1 receptor and the GIP receptor, a second gut-hormone signal. Liraglutide, an older daily GLP-1 medicine, is approved for weight management as Saxenda. These three are the peptides for weight loss that have cleared the full regulatory process in the US.

Now the other group. CJC-1295 and ipamorelin are growth hormone secretagogues, meaning they prompt the pituitary to release growth hormone. They have no action on GLP-1 receptors and no approved use in any country. AOD-9604 is a fragment of the growth hormone molecule. BPC-157 is a fragment of a stomach protein studied almost entirely in rodents. Calling these “like Ozempic” is a bit like calling a bicycle “like a car” because both have wheels. The mechanism, the evidence and the regulatory status share nothing except the word peptide.

One more wrinkle: a vial sold online as “semaglutide, research grade” is also not Ozempic. It has not been tested for purity, sterility or dose accuracy, and it is discussed later in this article.

Which peptides for weight loss are approved medicines?

Three peptides carry a weight-management approval in the US, and the evidence behind each is different in size and strength.

Semaglutide (Wegovy). The STEP 1 trial randomized 1,961 adults without diabetes to semaglutide or placebo, both with lifestyle counseling, for 68 weeks. Average weight change was about 14.9 percent in the semaglutide group versus 2.4 percent with placebo. The SELECT trial later showed a 20 percent relative reduction in heart attack, stroke or cardiovascular death among people with existing heart disease, from 8.0 percent to 6.5 percent over roughly three years. That is the only weight-management peptide with a proven cardiovascular outcome.

Tirzepatide (Zepbound). SURMOUNT-1 randomized 2,539 adults for 72 weeks. Average weight change ranged from about 15 percent to about 21 percent across the doses studied, versus about 3 percent with placebo. Tirzepatide is also approved for moderate to severe obstructive sleep apnea in adults with obesity, after trials showed fewer breathing interruptions during sleep.

Liraglutide (Saxenda). An earlier GLP-1 medicine with a smaller effect, around 5 to 8 percent average loss in its trials. Its long track record, including a large cardiovascular safety study in people with diabetes, remains part of the reassurance for the class.

Two peptides deserve a footnote. Tesamorelin is approved only to reduce excess abdominal fat in people with HIV-associated lipodystrophy; it is not approved for general weight loss and has not been shown to help with it. Sermorelin was once approved as a diagnostic test of growth hormone reserve and was withdrawn from the US market in 2008 for commercial reasons; websites now sell it for “body composition” without any trial support.

The approvals share one condition worth emphasizing: every trial paired the medicine with diet and activity advice. The numbers above describe the combination, not the injection alone.

How do GLP-1 peptides actually make people eat less?

Picture the end of a large holiday dinner, the moment when even a favorite dessert looks like work. That feeling is partly GLP-1. The hormone rises after food reaches the intestine and does several things at once, and the approved medicines amplify all of them.

In the brain, GLP-1 receptors sit in regions of the hypothalamus and brainstem that regulate appetite. Activating them lowers hunger and, in many trial participants, quiets what researchers call “food noise,” the intrusive thinking about eating between meals. People on these medicines consistently eat fewer calories, typically several hundred fewer per day in controlled feeding studies, without being told to.

In the stomach, the hormone slows emptying, so a meal sits longer and fullness lasts. This is also the source of the most common side effects: nausea, bloating and constipation are the same mechanism turned up too far.

In the pancreas, GLP-1 boosts insulin release when blood sugar is high and dampens glucagon, the hormone that tells the liver to release stored sugar. Because the effect depends on glucose being elevated, the risk of dangerous low blood sugar is small in people who are not also taking insulin or certain diabetes tablets.

Tirzepatide adds GIP receptor activation. GIP, glucose-dependent insulinotropic polypeptide, is another meal-triggered gut hormone. Its exact contribution to weight loss is still being worked out, but the combination produced larger average losses in head-to-head trials than semaglutide alone.

None of this involves “melting fat” or “boosting metabolism.” Resting metabolic rate does not rise on these medicines; if anything it falls slightly as weight comes off, as it does with any weight loss. The mechanism is appetite, and appetite is why the medicines stop working when they are stopped.

What the evidence actually says, graded by strength

Not all evidence carries the same weight. A useful ladder, from strongest to weakest: multiple large randomized controlled trials with hard outcomes; single randomized trials with body-weight endpoints; observational studies that follow people without assigning treatment; animal and laboratory studies; expert opinion and testimonials. Here is where each peptide sits.

Highest grade. Semaglutide is supported by a program of randomized trials totaling tens of thousands of participants, including SELECT, which measured heart attacks and strokes rather than pounds. Tirzepatide is supported by several large randomized trials for weight, sleep apnea and diabetes, with cardiovascular outcome trials reporting. Liraglutide has randomized weight trials plus a long safety record.

Middle grade. Retatrutide, cagrilintide-semaglutide and survodutide have completed or are completing phase 3 randomized trials, some reporting average losses above 20 percent. The data are real but still under regulatory review, and long-term safety follow-up is short. Investigational means exactly that: not approved, not for sale, not for self-use.

Low grade. AOD-9604 reached human trials two decades ago; they did not show meaningful weight loss and development stopped. Tesamorelin has randomized trials, but only in HIV-related fat accumulation.

No usable human evidence. CJC-1295, ipamorelin, BPC-157 and MOTS-c have rodent studies, small mechanistic studies of hormone levels, or nothing at all in people for weight. Growth hormone secretagogues do raise growth hormone and IGF-1 in humans, but raising a hormone is not the same as losing fat safely, and growth hormone itself has failed as an obesity treatment in trials.

The honest summary: the evidence for GLP-1-based medicines is among the strongest for any obesity treatment ever tested. The evidence for online research peptides, for weight, is essentially blank.

Prescription, investigational or research chemical: a side-by-side table

The categories below are regulatory and evidentiary, not marketing tiers. “Approved” means a national regulator has reviewed manufacturing quality, safety and efficacy data and permitted the product for a defined use.

Peptide	How it acts	Status for weight loss	Human weight evidence
Semaglutide	GLP-1 receptor agonist	Approved (US, UK, EU)	Large RCTs; cardiovascular outcome trial
Tirzepatide	GLP-1 and GIP agonist	Approved (US, UK, EU)	Large RCTs; sleep apnea RCTs
Liraglutide	GLP-1 receptor agonist	Approved	RCTs; long safety record
Retatrutide	GLP-1, GIP and glucagon agonist	Investigational	Phase 3 RCTs reporting
Cagrilintide + semaglutide	Amylin analogue plus GLP-1	Investigational	Phase 3 RCTs reporting
Tesamorelin	Growth hormone releasing	Approved only for HIV lipodystrophy	RCTs in that condition only
AOD-9604	Growth hormone fragment	Not approved anywhere	Early trials negative
CJC-1295, ipamorelin	Growth hormone secretagogues	Not approved; flagged as unsuitable for compounding in US	None for weight
BPC-157	Gastric protein fragment	Not approved; flagged as unsuitable for compounding in US	None for weight; rodent data only
MOTS-c	Mitochondrial-derived peptide	Not approved	None for weight

Two patterns jump out. Every approved entry works through gut-hormone appetite pathways, and every unapproved entry sold for “fat loss” works through something else, usually growth hormone. That is not a coincidence. Growth hormone pathways were tested for obesity decades ago and did not deliver.

The middle rows also matter. Investigational peptides have promising data, which is exactly why counterfeit versions appear online months after a trial is published. A phase 3 result is a reason for hope inside a clinical trial, not a reason to inject an unverified powder at home.

Research peptides for weight loss sold online: what is known about each

Scroll through a typical “research peptide” storefront and the same names recur. Here is what the medical literature, rather than the product page, says about each.

CJC-1295 and ipamorelin. Both stimulate growth hormone release and are usually sold as a pair. Small human studies confirm they raise growth hormone and IGF-1, a growth factor made by the liver. No randomized trial has measured body weight, and the theoretical concerns are not trivial: sustained IGF-1 elevation is linked in observational data to fluid retention, joint pain, insulin resistance and, over long periods, questions about cell growth. One early CJC-1295 trial program was halted after a participant death, though causation was never established.

AOD-9604. Marketed as “the fat-burning fragment” of growth hormone. It was tested in obese adults in Australian trials in the early 2000s. Weight loss was not significantly different from placebo, and the developer discontinued the program. It has never been approved for any use in humans anywhere.

BPC-157. Sold for healing, gut repair and, increasingly, “recovery during a cut.” The evidence base is rodent studies of tendon, muscle and stomach injury. There are no published randomized trials in people for any indication, let alone weight.

MOTS-c. A peptide encoded in mitochondrial DNA that improved metabolism in mice. Human data are limited to measuring blood levels; no weight trials exist.

5-Amino-1MQ, tesofensine and similar. Often listed alongside peptides but they are small molecules, not peptides at all, and equally unapproved for weight loss.

The regulatory position is plain. In the US, several of these compounds appear on a federal list of substances that pose significant safety risks and may not be compounded, and none holds marketing authorization in the US, UK or EU. “Research use only” is not a loophole for personal use; it is a statement that the seller has not verified the product is fit for a human body.

Compounded and grey-market semaglutide: what the label does and does not tell you

A second grey market runs alongside the research-peptide one, and it is more confusing because the name on the vial is a real medicine.

Compounding is the legal preparation of a customized medicine by a licensed pharmacy for an individual patient, for example when someone is allergic to an inactive ingredient. During the shortage years, US law temporarily allowed pharmacies to compound semaglutide and tirzepatide in volume. Those preparations were never reviewed by regulators for quality, and adverse-event reports during that period included dosing errors linked to unfamiliar vial-and-syringe formats and products containing different salt forms of the molecule than the approved medicine. With both shortages declared over in 2025, routine compounding of copies is no longer permitted, and anything still advertised under that banner sits outside the rules.

Online “research grade” semaglutide is a different tier again. Independent laboratory analyses of such products, reported in the medical literature, have found vials containing far less active peptide than labeled, vials containing more, bacterial contamination, and in some cases no semaglutide at all. Sterility matters because these products are injected. A contaminated vial can cause an abscess or a bloodstream infection; a mislabeled one can cause severe vomiting and dehydration from an unintended overdose.

Approved products are made under Good Manufacturing Practice, a regulated system that checks each batch for identity, potency and sterility, and are dispensed in devices designed to deliver a fixed amount. A vial with a peel-off label and a chemical name is not the same product, whatever the website says.

If a medicine like semaglutide is appropriate for you, that judgment and the prescription belong to a licensed clinician who can see your history, and the product should come through a licensed pharmacy. Anything else transfers the entire risk of quality control to the person holding the syringe.

What is the downside of taking peptides?

Even the approved medicines have real drawbacks, and the marketing rarely mentions them. Listing them is not fear; it is what informed consent looks like.

Gastrointestinal effects. Nausea affected roughly 44 percent of semaglutide participants in STEP 1 versus 16 percent on placebo, with diarrhea, vomiting and constipation also common. Most episodes were mild to moderate and eased over weeks, but about 4 to 7 percent of participants left trials because of side effects.

Gallbladder problems. Rapid weight loss by any method raises gallstone risk, and trials of GLP-1 medicines show a modest excess of gallbladder events.

Pancreatitis. Rare, but listed on every label; the classic warning sign is severe, persistent upper abdominal pain that may spread to the back.

Muscle loss. Body-composition substudies suggest that around a quarter to a third of the weight lost is lean tissue, similar to other forms of rapid weight loss. Adequate protein and resistance exercise are the evidence-based counterweights.

Weight regain. In the STEP 1 extension study, participants regained about two-thirds of the lost weight within a year of stopping. These medicines manage a chronic condition; they do not reset it.

Thyroid C-cell tumors occurred in rodents at high doses; the human relevance is unknown, and people with a personal or family history of medullary thyroid cancer are advised against the class.

Research chemicals add a different kind of downside: unknown unknowns. Growth hormone secretagogues can raise blood sugar and cause fluid retention. Unverified vials can be contaminated or misdosed. And because none of these compounds has a safety database, no one can tell you what the long-term risks are, because no one has looked.

Is there a best peptide for weight loss?

People ask this the way they ask for the best running shoe, and the honest answer has the same shape: it depends on the foot.

On average weight change alone, tirzepatide produced larger losses than semaglutide in the one head-to-head randomized trial published so far, roughly 20 percent versus 14 percent over 72 weeks. Retatrutide’s phase 3 results, if they hold up through review, suggest larger figures still. Averages, though, hide a wide spread. In every trial, some participants lost more than 25 percent of their body weight and some lost less than 5 percent, on the same medicine.

Other endpoints reshuffle the ranking. Semaglutide is the only one with a completed cardiovascular outcome trial in people without diabetes showing fewer heart attacks and strokes; for someone with established heart disease, that evidence may matter more than a few extra percentage points. Tirzepatide holds the sleep apnea indication. Liraglutide has the longest safety record and may suit someone who does poorly with the newer agents.

Then there are the factors no ranking captures: your other medicines, kidney function, history of pancreatitis or gallbladder disease, pregnancy plans, and how your body handles nausea. This is why the choice belongs to the prescribing clinician, who can weigh those variables against the trial data.

What about “stacking,” the online practice of combining several research peptides for supposedly additive effects? No human study has tested any such combination for weight. Combining compounds with unknown individual safety profiles does not make the result more predictable.

The medicines also work best in a context. Every trial delivered them alongside a reduced-calorie diet and increased activity, and participants who kept protein intake up and did resistance training preserved more muscle. The “best” peptide is the approved one your clinician judges appropriate, used inside a plan you can sustain.

Who is eligible for GLP-1 peptide injections for weight loss?

Eligibility is defined by regulators and health systems, not by a questionnaire on a website, and the criteria are more specific than “wants to lose weight.”

In the US, semaglutide and tirzepatide are approved for chronic weight management in adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Body mass index, or BMI, is weight in kilograms divided by height in meters squared; it is a population screening tool with known limits, and clinicians increasingly use waist measurement and health conditions alongside it. Semaglutide is also approved for adolescents aged 12 and older with obesity, based on a separate randomized trial.

In England, NHS guidance routes these medicines through specialist weight management services or, since 2025, a phased primary care program for tirzepatide that began with people who have a BMI of 40 or higher plus several weight-related conditions, with lower thresholds adjusted for some ethnic groups in whom health risks rise at lower BMI.

Certain people are advised against the class regardless of weight: anyone with a personal or family history of medullary thyroid cancer or a rare syndrome called MEN 2, anyone who is pregnant or planning pregnancy, and people with a history of pancreatitis need individual assessment. Because the medicines slow stomach emptying, they also change how some oral medicines are absorbed, which is one reason the full medication list matters.

Meeting the criteria does not make the medicine mandatory. Structured lifestyle programs, behavioral therapy and, for some, bariatric surgery remain evidence-based options with their own trial data. Which path fits is a conversation, and the prescribing clinician makes the final call.

Common myths about peptides for weight loss, corrected

Viral claims travel faster than trial results. Here are the ones that appear most often, and what the evidence says.

“Peptides are natural, so they are safer than drugs.” Semaglutide is a peptide and a drug. Botulinum toxin is a natural peptide and one of the most potent poisons known. Origin tells you nothing about safety; testing does.

“Research peptides are the same molecules as the prescription, just cheaper.” For growth hormone secretagogues and BPC-157, they are entirely different molecules with no weight-loss evidence. For vials labeled semaglutide, laboratory testing has repeatedly found wrong potency, contamination or no active ingredient.

“GLP-1 medicines melt fat directly.” They reduce appetite and slow digestion. Weight falls because people eat less. Resting metabolism does not rise.

“Once you reach your goal, you can stop.” Randomized data show most of the weight returns within a year of stopping. Obesity behaves like other chronic conditions in this respect.

“Ipamorelin builds muscle while you lose fat.” It raises growth hormone in the short term. Growth hormone given to adults without deficiency has produced modest changes in body composition in some studies but no meaningful fat loss in obesity trials, along with joint pain, swelling and insulin resistance.

“Doctors are hiding these peptides because they work too well.” The compounds were tested and either failed, as AOD-9604 did, or were never taken into proper trials because early signals did not justify the cost. Absence of a trial is absence of evidence, not evidence of suppression.

“A weight-loss peptide fixes everything.” The strongest trial data show meaningful improvements in blood pressure, blood sugar and, for semaglutide, cardiovascular events. They do not show effects on longevity in healthy-weight people, and no trial supports use in anyone below the approved BMI thresholds.

When to see a doctor about peptides for weight loss

Two situations call for a clinician, and they are not the same conversation.

Before starting anything. If you are considering a peptide medicine, a licensed prescriber can check whether you meet the criteria, review your other medicines and conditions, and decide whether this class is appropriate at all. That appointment is also the right place to ask about compounded or online products you have seen; a clinician can explain what is and is not regulated where you live. Every decision about starting, changing or stopping a prescription belongs to that clinician.

If you are already using any peptide, prescribed or not, and notice these red flags, seek medical care promptly:

• Severe or persistent abdominal pain, especially pain that spreads to the back, with or without vomiting, which can signal pancreatitis.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or pale stools, which can signal a gallbladder problem.
• Vomiting that prevents you from keeping fluids down for more than a day, dizziness on standing, or very little urine, which point to dehydration.
• A lump or swelling in the neck, trouble swallowing, or persistent hoarseness.
• Confusion, sweating, shakiness or a racing heart, particularly if you also take insulin or diabetes tablets, which can indicate low blood sugar.
• Redness, warmth, pus or spreading pain at an injection site, or fever after injecting an unverified product.
• Sudden vision changes, if you have diabetes.
• Any new or worsening low mood or thoughts of self-harm.

Call emergency services for chest pain, difficulty breathing, fainting or signs of a severe allergic reaction such as facial swelling or hives with breathing trouble.

If you have used a research chemical or an online vial, tell the clinician exactly what it was labeled, even if the label was a chemical name; it changes the assessment. Nobody in that room is there to judge. They are there to keep you safe.

Frequently asked questions

Do peptides really work for weight loss?

The approved ones do, with strong evidence. Semaglutide and tirzepatide produced average losses of roughly 15 to 21 percent of body weight in large randomized trials when combined with diet and activity changes, far more than placebo. The peptides sold online as research chemicals, including CJC-1295, ipamorelin and BPC-157, have no randomized human trials showing weight loss, so there is no basis for saying they work.

What is the downside of taking peptides?

For approved GLP-1 medicines, the main downsides are nausea, vomiting and constipation, a small excess of gallbladder problems, rare pancreatitis, some loss of muscle along with fat, and substantial weight regain if the medicine is stopped. Research chemicals carry a different downside: no safety data at all, plus the risk that an unverified vial is contaminated, misdosed or not the compound on the label.

Are peptides the same as Ozempic?

Ozempic is one peptide, semaglutide, approved for type 2 diabetes; the same molecule is approved for weight management as Wegovy. Most products marketed as peptides are different molecules with different mechanisms and no approval. Growth hormone secretagogues such as ipamorelin do not act on the GLP-1 pathway at all, and an online vial labeled semaglutide has not been verified to contain the real medicine.

What is the best peptide for weight loss?

There is no single best option. Tirzepatide produced the largest average loss in head-to-head trial data, semaglutide is the only one with proven reductions in heart attacks and strokes, and liraglutide has the longest safety record. The right choice depends on your health conditions, other medicines and tolerance of side effects, which is why the decision rests with a prescribing clinician.

Are research peptides for weight loss legal to buy?

Selling them labeled for research is often legal; selling them for human use is not, and no country has authorized CJC-1295, ipamorelin, AOD-9604 or BPC-157 as medicines. In the US, several appear on a federal list of substances deemed unsuitable for compounding because of safety concerns. The “research use only” label means the seller makes no claim the product is safe or pure for a human body.

How do GLP-1 peptides cause weight loss?

They copy a gut hormone released after meals. Activating GLP-1 receptors in the brain lowers hunger and intrusive food thoughts, slowing stomach emptying prolongs fullness, and in the pancreas insulin release improves when blood sugar is high. People simply eat less, typically several hundred fewer calories a day in feeding studies. Metabolism does not speed up; the effect is entirely on intake.

Do peptide injections for weight loss cause muscle loss?

Some, yes. Body-composition studies of GLP-1 medicines suggest roughly a quarter to a third of the weight lost is lean tissue, a proportion similar to other forms of rapid weight loss such as very low calorie diets. Adequate protein intake and regular resistance training preserved more muscle in trial participants, which is why both are part of standard advice alongside these medicines.

What happens when you stop taking a weight-loss peptide?

Appetite returns and most of the weight tends to follow. In the STEP 1 extension study, participants regained about two-thirds of what they had lost within a year of stopping semaglutide, and blood pressure and blood sugar improvements faded too. Regulators and guidelines therefore describe these medicines as long-term management of a chronic condition. Any decision to stop should be made with the prescribing clinician.

Is compounded semaglutide the same as Wegovy?

No. Compounded versions were prepared by pharmacies under a temporary shortage allowance and were never reviewed by regulators for potency, purity or sterility. Some contained different salt forms of the molecule, and dosing errors were reported with vial-and-syringe formats. With shortages declared over in 2025, routine compounding of these copies is no longer permitted in the US. Approved products come through licensed pharmacies in regulated devices.

Who should not use peptides for weight loss?

People with a personal or family history of medullary thyroid cancer or the genetic syndrome MEN 2 are advised against GLP-1 medicines, as are those who are pregnant or planning pregnancy. A history of pancreatitis or severe gastrointestinal disease needs individual assessment. People below the approved BMI thresholds have no trial evidence supporting use. Research chemicals have no established safe group at all and are not for self-use.

References

• Semaglutide Injection: MedlinePlus Drug Information
• Obesity: Treatment: NHS
• GLP-1 Agonists: Cleveland Clinic

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.